Trial · NCT03445559
A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging
NCT03445559, Not applicable, Active not recruiting, VA Office of Research and Development; results first posted 2025-02-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging. Trials, record NCT03445559. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03445559
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging
- NCT number
- NCT03445559
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 58 participants, actual
- Lead sponsor
- VA Office of Research and Development
- Conditions
- Prostate Cancer
- Interventions
- Clinical Order Check, Academic Detailing, Audit and Feedback
- First posted
- 2018-02-26
- Last updated
- 2026-06-04
- Results first posted
- 2025-02-14
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Facility-level Inappropriate Prostate Cancer Bone Scan Imaging Rates | Through study completion, an average of 4 years | Facility-level utilization of bone scan imaging among men with newly diagnosed, low-risk prostate cancer. (Inappropriate Imaging according to NCCN guidelines) |
| Primary | Facility-level Appropriate Prostate Cancer Bone Scan Imaging Rates | Through study completion, an average of 4 years | Facility-level utilization of bone scan imaging among men with newly diagnosed, high-risk prostate cancer. (Appropriate Imaging according to NCCN guidelines) |
| Secondary | Individual-level Inappropriate Prostate Cancer Imaging Rates | Through study completion, an average of 4 years | Provider-level utilization of nuclear medicine bone scan among men with newly diagnosed, low-risk prostate cancer (Inappropriate Imaging). Imaging is not recommended to stage low-risk prostate cancer men with PSA\<10, Gleason\<7, and clinical stage \<T3. |
| Secondary | Individual-level Appropriate Prostate Cancer Imaging Rates | Through study completion, an average of 4 years | Provider-level utilization of bone scans among men with newly diagnosed, high-risk prostate cancer. (Appropriate Imaging) |
| Secondary | Provider Attitudes Regarding Prostate Cancer Imaging Guidelines and the Behavioral Intervention | Through study completion, an average of 4 years | Qualitative outcome assessed through semi-structured, in-depth interviews with participating providers |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Facility-level Inappropriate Prostate Cancer Bone Scan Imaging Rates | Through study completion, an average of 4 years | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Facility-level Appropriate Prostate Cancer Bone Scan Imaging Rates | Through study completion, an average of 4 years | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Individual-level Inappropriate Prostate Cancer Imaging Rates | Through study completion, an average of 4 years | Clinical provider encounters (urologists, nurse practitioners, and physician assistants) that can order imaging for staging of prostate cancer patients. Patients may have seen multiple unique providers during the study period. | percentage of inappropriate bone scans | MEDIAN |
| SECONDARY | Individual-level Appropriate Prostate Cancer Imaging Rates | Through study completion, an average of 4 years | Clinical provider encounters (urologists, nurse practitioners, and physician assistants) that can order imaging for staging of prostate cancer patients. Patients may have seen multiple unique providers during the study period. | percentage of appropriate bone scans | MEDIAN |
| SECONDARY | Provider Attitudes Regarding Prostate Cancer Imaging Guidelines and the Behavioral Intervention | Through study completion, an average of 4 years |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Facility-level Inappropriate Prostate Cancer Bone Scan Imaging Rates | Control | 141 | Participants | ||
| Facility-level Inappropriate Prostate Cancer Bone Scan Imaging Rates | Intervention | 109 | Participants | ||
| Facility-level Appropriate Prostate Cancer Bone Scan Imaging Rates | Control | 396 | Participants | ||
| Facility-level Appropriate Prostate Cancer Bone Scan Imaging Rates | Intervention | 428 | Participants | ||
| Individual-level Inappropriate Prostate Cancer Imaging Rates | Control | 10.6 | Inter-Quartile Range 8 to 19 | percentage of inappropriate bone scans | |
| Individual-level Inappropriate Prostate Cancer Imaging Rates | Intervention | 9.1 | Inter-Quartile Range 0 to 14 | percentage of inappropriate bone scans | |
| Individual-level Appropriate Prostate Cancer Imaging Rates | Control | 89.4 | Inter-Quartile Range 81 to 92 | percentage of appropriate bone scans | |
| Individual-level Appropriate Prostate Cancer Imaging Rates | Intervention | 90.9 | Inter-Quartile Range 86 to 100 | percentage of appropriate bone scans |
Source ClinicalTrials.gov
Participant flow360
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 1: 3 Months of Control, Then 33 Months of Intervention | 30 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 2: 6 Months of Control, Then 30 Months of Intervention | 25 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 3: 9 Months of Control, Then 27 Months of Intervention | 10 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 4: 12 Months of Control, Then 24 Months of Intervention | 30 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 5: 15 Months of Control, Then 21 Months of Intervention | 17 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 6: 18 Months of Control, Then 18 Months of Intervention | 41 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 7: 21 Months of Control, Then 15 Months of Intervention | 24 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 8: 24 Months of Control, Then 12 Months of Intervention | 9 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 9: 27 Months of Control, Then 9 Months of Intervention | 27 | |
| Step 0: Mar 2018 to May 2018 | STARTED | Sequence Site 10: 30 Months of Control, Then 6 Months of Intervention | 8 |
1 to 10 of 360Source ClinicalTrials.gov
See all 360 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Control | 1 | 1,149 |
| Total, all-cause mortality | Intervention | 1 | 1,267 |
| Total, all-cause mortality | Intervention Providers | 0 | 58 |
| Total, other adverse events | Control | 0 | 1,149 |
| Total, other adverse events | Intervention | 0 | 1,267 |
| Total, other adverse events | Intervention Providers | 0 | 58 |
| Total, serious adverse events | Control | 0 | 1,149 |
| Total, serious adverse events | Intervention | 0 | 1,267 |
| Total, serious adverse events | Intervention Providers | 0 | 58 |
Source ClinicalTrials.gov
Papers19
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Intervention vs Control: Facility-level Appropriate Prostate Cancer Bone Scan Imaging Rates | Trial comparisons |
| Intervention vs Control: Facility-level Inappropriate Prostate Cancer Bone Scan Imaging Rates | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03445559
GET https://conductscience.org/api/trials/v1/NCT03445559/flow?page=2